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Addictions
Tobacco smoking: 
options for helping 
smokers to quit
Background
Although great progress has been made on tobacco control, 
smoking remains one of the most important causes of 
preventable disease and death in the Australian population. 
The general practice team has much to offer in helping 
smokers to quit. 
Objective
This article provides practical advice on structuring smoking 
cessation support in primary care using the 5As (Ask, Assess, 
Advise, Assist and Arrange follow-up) framework. Up-to-date 
information on pharmacotherapy and issues for special groups 
are also covered.
Discussion 
The chances of successful quitting are maximised if the 
patient receives behavioural support combined with drug 
treatment, if nicotine-dependent. Special groups needing 
support include Aboriginal and Torres Strait Islander peoples, 
people with mental illness and pregnant women.
Keywords
tobacco smoking; preventive medicine; smoking cessation 
products; treatment
There has been great progress in tobacco control in 
Australia. Smoking rates in the population have fallen 
and, currently, approximately 15% of people aged 14 years 
and over are daily smokers.1 However, certain groups, in 
particular Aboriginal and Torres Strait Islander peoples, 
have much higher smoking rates.2 Smoking remains 
common in people with mental health problems.3 Despite 
the falling overall prevalence, tobacco use still causes a 
higher burden of disease than any other behavioural risk 
factor. On average, smokers live 10 years less than non-
smokers and 60% of long-term smokers will die prematurely 
from a smoking-related disease.4,5 Most smokers are 
nicotine-dependent and for these people smoking can be 
considered a chronic medical illness that requires ongoing 
care.6
Most smokers would like to quit and approximately 40% have made 
at least one attempt to do so in the past year.7 The good news is that 
smoking cessation has substantial and rapid health benefits.4 Primary 
care has a major role in helping smokers to quit successfully. Brief 
advice from a general practitioner (GP) increases cessation rates 
by about two-thirds, compared with no advice, and is highly cost-
effective.8 Practice nurses also have an important role in providing this 
support.9 
The 5As approach
The 5As provide health professionals with a framework for structuring 
smoking cessation support. The elements of the 5As are ask, assess, 
advise, assist and arrange follow-up.10 Figure 1 shows this approach 
in detail. The key features are:
•  Ask: regularly ask all patients if they smoke and record the 
information in the medical record.
•  Advise: advise all smokers to quit in a clear, unambiguous way 
such as ‘the best thing you can do for your health is to stop 
smoking’.
•  Assess: assessment of interest in quitting helps to tailor advice 
to each smoker’s needs and stage of change. Nicotine dependence 
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• Describe withdrawal symptoms and cravings and explore ways of 
managing these (eg distraction strategies such as doing exercise).
• Agree on a quit date and promote the ‘not-a-puff’ rule.
• Address barriers to quitting and how to overcome these (Table 1). 
• Assist with choice of medicines and ensure that patients have a 
realistic expectation of how these medicines can aid quit attempts, 
for example, by reducing withdrawal symptoms. 
• Identify smoking triggers and discuss strategies to cope with them. 
For example, minimal or no alcohol in the early weeks of a quit 
attempt is advised.
• Get support from family and friends, patient support services and 
printed materials. 
• Promote lifestyle changes, such as exercise and avoiding high-risk 
situations.
• Provide relapse prevention advice.
 Relapse is defined as a return to regular smoking. It is most 
common early in the quit attempt (in the first 8 days).13 Follow up 
with professional and social support is encouraged to try to prevent 
relapses but there are currently no proven behavioural interventions.14 
Most smokers make repeated attempts to quit before finally achieving 
long-term abstinence. Each attempt is a valuable learning experience, 
making the next attempt more likely to succeed. Smokers should be 
encouraged to keep trying to quit and to make use of evidence-based 
support to maximise their chance of success.
Smoking cessation pharmacotherapy
Meta-analyses of clinical trials provide high-level evidence that 
medicines can assist smoking cessation.15 Pharmacotherapy should be 
offered to people who are nicotine-dependent and is most effective 
Assessment of other relevant problems, such as mental health 
conditions, other drug dependencies and comorbidities, is necessary 
to develop a comprehensive treatment plan.
•  Assist: all smokers should be offered help to quit.
•  Arrange: follow-up visits have been shown to increase the 
likelihood of long-term abstinence and are especially useful in the 
first few weeks after quitting.
When time is short, the approach of ‘very brief advice’ developed 
by the United Kingdom National Centre for Smoking Cessation and 
Training (see Resources) is an alternative. The steps for this are: 
establish smoking status (ASK), ADVISE that the best way of quitting is 
with a combination of behavioural support and drug treatment, REFER 
– provide a referral to a specialised service.
 In the Australian context, referral options outside the general 
practice include:
• Quitline (137 848), which provides free telephone counselling 
Australia-wide. Referral from general practice to the local state or 
territory Quitline can be provided by fax or email (Victoria and SA) 
and some states (Victoria, SA and NSW) now provide feedback to 
the referring practitioner. 
• The Australian Association of Smoking Cessation Professionals 
website (www.aascp.org.au) has a searchable listing of accredited 
tobacco treatment specialists. 
Counselling and behavioural therapy
If support is being provided in the practice by the GP or practice 
nurse, the following counselling and behavioural strategies can assist 
smokers to quit successfully.11,12
• Build rapport and boost motivation.
Table 1. Barriers to quitting smoking
Barrier Discussion
Weight gain Weight gain after quitting is, on average, 4–5 kg after 12 months. The health benefits of quitting is 
almost always greater than the health effect of the extra weight. Drinking water and choosing low-
calorie foods can help minimise weight gain. Suggest focus on stopping smoking in the short term and 
deal with any weight gain later. About 1 in 5 quitters do not gain weight.
Coping with 
stress
Explain to smokers that smoking actually increases stress and that they will be more relaxed after 
quitting. Some smokers experience repeated episodes of anxiety and restlessness during the day due 
to nicotine withdrawal between cigarettes. Understandably, when a cigarette relieves these symptoms 
they assume that the cigarette is relaxing them. Other healthier and more effective ways to relax 
include breathing and progressive muscle relaxation techniques.
Withdrawal 
from nicotine
Cravings last only 2–3 minutes, although that may feel like forever! Cravings get weaker and less 
frequent over time but can persist for many years. Nicotine withdrawal symptoms are at their worst 
in the first week and typically last 2–4 weeks. They can usually be controlled with stop-smoking 
medications and behavioural strategies such as distraction techniques and avoiding smoking triggers.
Fear of failure Explain that most ex-smokers made a number of quitting attempts before finally being successful. 
Unsuccessful attempts at quitting can be reframed as learning experiences and can increase the 
chance of success next time. Furthermore, with the right professional counselling, support and 
medication, the odds of success are much higher.
Peer or social 
pressure
It may be best to avoid friends who smoke for the first few weeks. Suggest asking friends not to offer 
cigarettes and, if possible, not to smoke around your patient. If necessary, leave the room while they 
smoke. Discuss how to respond if offered a cigarette. If the partner smokes, ask him or her to smoke 
outside.
FOCUS Tobacco smoking: options for helping smokers to quit
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Figure 1. The 5As structure for health professionals for smoking cessation.  
Adapted with permission from the Royal Australian College of General Practitioners10
Ask all patients
Do you smoke tobacco?
• Record smoking status 
(current smoker)
Ask all patients
Have you ever smoked?
• Affirm choice not to 




• Assess stage of change: 
 – ‘How do you feel about your 
smoking at the moment?’ 
 – Are you ready to stop 
smoking now?’
• Record stage of change
• Assess nicotine dependence
• Affirm decision to quit and record smoking status 
(ex-smoker)
• Give relapse prevention advice if quit <1 year, 
and ongoing encouragement for 5 years
Assess nicotine dependence
• Nicotine dependence can be assessed by asking:
 – How many minutes after waking to first cigarette?
 – Number of cigarettes per day?
 – What cravings or withdrawal symptoms in previous quit attempts?
• Smoking within 30 minutes of waking, smoking more than 10 cigarettes per 
day and history of withdrawal symptoms in previous quit attempts are all 
markers of nicotine dependence
• Pharmacotherapy for dependent smokers is proven to double the chances of 
successfully quitting
Advise
All smokers should be advised to quit in a way that is clear but non-confrontational
eg. ‘The best thing you can do for your health is to quit smoking’
Assist – not ready
• Discuss the benefits 
of quitting and risks 
of continued smoking
• Provide information 
about not exposing 
others to passive 
smoking
• Advise that help is 
available when they 
are ready
Assist – unsure
• Do motivational 
interviewing: ‘What are 
the things you like and 
don’t like about your 
smoking?’
• Explore motivation and 
barriers to quitting
• Offer written information 
(eg. Quit Kit) and referral 
to Quitline 13 7848 or 
a tobacco treatment 
specialist
Assist – ready
• Affirm and encourage
• Provide a Quit Kit and 





• Discuss relapse 
prevention
• Offer referral to Quitline 
13 7848 or a tobacco 
treatment specialist 
Assist – action  
and maintenance
• Congratulate
• Discuss relapse 
prevention
• Review and reinforce 
benefits of quitting
• Offer written 
information (e.g. Quit 
Kit) and referral to 
Quitline 13 7848 or 
a tobacco treatment 
specialist
Successful quitter
• Congratulate and 
affirm decision to quit
• Discuss relapse 
prevention
• Offer ongoing 
encouragement for 
at least 5 years after 
quitting
Relapse
• Offer support and 
reframe as a learning 
experience
• Explore reasons for 
relapse and lessons for 
future quit attempts
• Offer ongoing support
• Ask again at future 
consultations
Arrange follow up
• For patients attempting to quit, arrange follow-
up visits, if possible
• At these visits:
 – congratulate and affirm decision
 – review progress and problems
 – encourage continuance of pharmacotherapy
 – discuss relapse prevention
 – encourage use of support services
OR
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Bupropion
Bupropion is another effective medicine with similar efficacy as 
NRT monotherapy.15 The major concern is a small risk of seizure 
(approximately 1 in 1000). Bupropion is contraindicated in patients 
with a history of seizures, eating disorders and in patients taking 
monoamine oxidase inhibitors. It should be used with caution in 
people taking medications that can lower seizure threshold, such as 
antidepressants and oral hypoglycaemic agents.10 The duration of 
treatment is 8 weeks.
What are other approaches to 
supporting smoking cessation?
Currently, there is considerable debate about whether e-cigarettes 
have a role in assisting smoking cessation. E-cigarettes are battery-
powered devices that deliver nicotine in a vapour. There is some 
evidence that e-cigarettes can relieve cravings and other symptoms 
of nicotine withdrawal but there is limited evidence so far on their 
efficacy as aids to cessation and major concerns about their current 
unregulated status.19,20 E-cigarettes have the potential to act as a 
gateway to smoking and undermine progress on tobacco control by 
renormalising smoking behaviour.21 
Promising areas of research include the use of exercise to assist 
smoking cessation and the role of mindfulness strategies.22,23 
Special groups
Several population groups have either higher rates of smoking or 
greater risk of adverse effects. One in two Aboriginal and Torres Strait 
Islander adults smokes and smoking is the largest single risk factor 
contributing to the health gap between Aboriginal and Torres Strait 
Islander and non-Indigenous populations. Smoking rates in prisoners 
are around 83%.24 One in three people with mental illness smokes and 
the level of nicotine-dependence is usually higher than in the general 
population.3 There is evidence that people with mental health problems 
are just as motivated to quit but the intensity and duration of support 
needed is greater.25–27 
 Pregnant women are in an important group due to the adverse 
effects of smoking on the fetus and the increased risk of pregnancy 
complications. Counselling interventions reduce the proportion of 
women who continue to smoke in late pregnancy by about 6%.28 
There is inconclusive evidence on the efficacy of NRT in pregnancy.29 
However, expert opinion is that use of NRT in pregnancy is less 
harmful than continued smoking.30 If NRT is used, the possible risks 
and benefits should be discussed. Fast-acting oral forms are generally 
preferred to reduce total nicotine dose. For a more detailed discussion 
of smoking in pregnancy see the article by Mendelsohn in the January/
February 2014 edition of AFP.31 
Effects of smoking and smoking 
cessation on drug metabolism 
Chemicals in tobacco smoke accelerate the metabolism of many 
commonly used drugs by inducing the cytochrome P450 enzyme 
when used in combination with behavioural support. The medicines 
approved for smoking cessation in Australia are nicotine replacement 
therapy (NRT), varenicline and bupropion. These medicines have been 
shown to be effective in a range of patient populations including 
smokers with depression, schizophrenia, and cardiac and respiratory 
diseases. A recent Cochrane network analysis concluded that 
combination NRT (nicotine patch combined with a fast-acting oral form) 
and varenicline are the most effective forms of drug treatment and 
work equally well.15 Bupropion and NRT monotherapy are equivalent in 
efficacy.15 The choice of pharmacotherapy should be guided by clinical 
suitability and patient preference (Figure 2).10 Even when smokers 
receive pharmacotherapy and professional support, overall cessation 
rates from treatment are modest: 25–30% of smokers quit on any given 
attempt10,15 (Figure 3).
Nicotine replacement therapy
NRT is available in a long-acting form (nicotine patch) and a variety 
of fast-acting oral forms (gum, inhalator, mouth spray, lozenge, oral 
strip). All forms of NRT monotherapy have similar efficacy in increasing 
long-term cessation, compared with placebo (relative risk 1.60, 95% 
confidence interval 1.53–1.68).16 There is increasing evidence, however, 
that combining the patch with an oral form of NRT is more effective 
than monotherapy and should be offered to all nicotine-dependent 
smokers using NRT.16 Pre-cessation treatment with a nicotine patch 
(usually started 2 weeks before quit day) has also been shown to 
improve success rates, compared with starting the patch on quit day. As 
is the case with all forms of pharmacotherapy for smoking cessation, it 
is important to help patients understand that to gain maximum benefit 
they need to take a sufficient dose of NRT to relieve cravings and 
withdrawal symptoms. NRT should also be taken for a sufficient length 
of time, generally at least 8–12 weeks. A helpful analogy is a plaster 
for a fracture – the support needs to be in place for long enough for the 
healing process to occur.
Varenicline
Varenicline is a nicotinic receptor partial agonist, which acts centrally 
to relieve cravings and withdrawal symptoms as well as reducing 
the rewarding effect of smoking. Varenicline is the most effective 
monotherapy currently available – a Cochrane network meta-analysis 
found it more than doubled sustained abstinence rates at 6 months 
follow-up, compared with placebo (risk ratio 2.88, 95% CI 2.40–3.47).15 
Nausea occurs in about 30% of users but can be minimised by 
gradually up-titrating the dose and having the tablets with food.17 
Although there have been concerns about neuropsychiatric adverse 
effects with varenicline, the evidence from a recent meta-analysis 
is that, compared with placebo, there is no increase in rates of 
suicidal events, depression or aggression/agitation in patients taking 
varenicline. This was the case in smokers with and without a history of 
psychiatric disorders.18 The usual duration of treatment is 12 weeks and 
for those who have quit successfully at the end of treatment, a second 
course of 12 weeks can be prescribed to reduce relapse.
FOCUS Tobacco smoking: options for helping smokers to quit
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CYP1A2. This can substantially lower serum concentrations and 
effectiveness of these drugs in smokers (Table 2). Conversely, blood 
levels of these medications may rise when smoking is stopped. 
Patients should be monitored for adverse effects, and dose reductions 
may be required. Particular care is needed for drugs with a narrow 
therapeutic index, such as clozapine, olanzapine and warfarin.32 
Harm reduction
Simply cutting down on smoking has not been shown to be sustainable 
or have health benefits but there is some evidence to support harm 
reduction using NRT. The most important finding is that in smokers 
unwilling or unable to quit, cutting down with NRT nearly doubles the 
chances of smokers progressing to quitting altogether.33 
Choice of pharmacotherapy
• Suggest therapy based on assessment of clinical 
suitability and patient preference
Nicotine replacement therapy 
(NRT)
Clinical suitability
Can be used in all groups of 
smokers including adolescents. 
Use with caution in pregnant 
women and patients with 
unstable cardiovascular disease 
(check product information [PI]).
Patient choice
• Reasons to prefer:
• Availability without 
prescription
• Concerns about side effects of 
varenicline and bupropion
• Can be used in pregnancy after 
discussion of risks and benefits




Can be used in adult smokers 
including those with chronic 
illnesses. Contraindicated in 
pregnancy and under the age 
of 18. Caution with significant 
psychological/psychiatric disease. 
Nausea in 30% of patients. Reduce 




• on current evidence, varenicline is 
the most effective monotherapy 
• oral non-nicotine preparation
• evidence of benefit in chronic 
disease
• lack of drug interactions.
Bupropion sustained release
Clinical suitability
Can be used in adult smokers 
including those with chronic 
illnesses. Contraindicated in 
patients with current or past 
seizures, concurrent use of 
monoamine oxidase inhibitors, 
pregnancy. Caution with other 
conditions or drugs that lower 
seizure threshold (check PI).
Patient choice
Reasons to prefer:
• oral non-nicotine preparation
• relapse in past using NRT
• evidence of benefit in chronic 
disease and depression.
• Discuss benefit of follow up 
visits, especially if there are 
adverse effects such as skin 
irritation, sleep disturbance
• Encourage use of support 
services
• Encourage completion of at 
least 8 weeks of therapy 
• Consider combination NRT 
(patch and quick-acting oral 
form) if highly dependent or 
withdrawal not controlled on 
monotherapy
• Arrange further follow-up visits 
as needed.
• Give initial prescription and 
arrange follow-up visit 
• Encourage use of support services
• At follow up, review progress and 
common adverse effects such as 
nausea and abnormal dreams
• Check for neuropsychiatric 
symptoms
• Encourage completion of 12 weeks 
of therapy
• If quit further 12 weeks available 
on PBS to reduce relapse
• Arrange further follow-up visits as 
needed.
• Give initial prescription and 
arrange follow-up visit
• Encourage use of support 
services
• At follow up, review progress 
and common adverse effects 
such as insomnia, headache 
and dry mouth
• Monitor for allergy problems 
(skin rash) 
• Encourage completion of 8 
weeks of therapy
• Arrange further follow-up 
visits as needed.
Figure 2. Pharmacotherapy treatment algorithm for nicotine dependent smokers.  
Reproduced with permission from the Royal Australian College of General Practitioners10 
FOCUSTobacco smoking: options for helping smokers to quit
REPRINTED FROM AUSTRALIAN FAMILY PHYSICIAN VOL. 43, NO. 6, JUNE 2014  353
advice on smoking cessation programs to Pfizer and GlaxoSmithKline 
Australia and has received support to attend smoking cessation 
conferences; Colin Mendelsohn has received honoraria for teaching, 
consulting and conference expenses from Pfizer, GlaxoSmithKline and 
Johnson & Johnson Pacific. 
Provenance and peer review: Commissioned, externally peer reviewed.
Resources
• Australian Smoking Cessation Guidelines, www.racgp.org.au/your-
practice/guidelines/smoking-cessation/ 
• United States Smoking Cessation Guidelines, www.ahrq.gov/
professionals/clinicians-providers/guidelines-recommendations/
tobacco/clinicians/treating_tobacco_use08.pdf.
• Tobacco in Australia: Facts and issues. 4th edn. Melbourne: Cancer 
Council Victoria; 2012. A comprehensive review of the major 
issues in smoking and health in Australia, compiled by the Cancer 
Council Victoria, www.TobaccoInAustralia.org.au. 
• Society for Research on Nicotine and Tobacco and the Society for 
the Study of Addiction. The website has links to clinical practice 
Table 2. Drugs that interact with smoking: blood levels rise after cessation of smoking
Class Medication
Antipsychotics Olanzapine, clozapine,
Antidepressants Duloxetine, fluvoxamine, tricyclic antidepressants, mirtazapine
Antianxiety agents Alprazolam, oxazepam, diazepam
Cardiovascular drugs Warfarin, propranolol, verapamil, flecainide
Clopidogrel (efficacy increased in smokers)
Diabetes Insulin, metformin
Other Naratriptan, oestradiol, ondansetron, theophylline, dextropropoxyphene
Others Caffeine, alcohol
Conclusion
The general practice team has much to offer in helping smokers to 
quit. This can range from a very brief intervention where smokers 
are identified and referred for treatment, to a structured program of 
evidence-based support provided within the practice. The chances of 
successful quitting are maximised if the patient receives a combination 
of behavioural support and drug treatment.
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Figure 3. Long-term (>6 month) quit rates for widely available cessation medications15–17 
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29. Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. 
Pharmacological interventions for promoting smoking cessation during 
pregnancy. Cochrane Database Syst Rev 2012;CD010078. 
30. Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking 
cessation in pregnancy. Drug Saf 2001;24:277–322. 
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women. Aust Fam Physician 2014;43:46–51.
32. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: poten-
tially risky effects on prescribed medications. J Clin Nurs 2009;18:1533–40. 
33. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco 
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guidelines for cessation from around the world, www.treatobacco.
net provides information on treatment of tobacco dependence 
• UK National Centre for Smoking Cessation and Training provides 
online access to the Very Brief Advice Training Module, www.
ncsct.co.uk/
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